March 8, 2017 10:24 AM IRVINE, CA--(Marketwired
Post# of 306
(Total Views: 4652)
Posted On: 03/09/2017 12:57:29 PM
March 8, 2017 10:24 AM
IRVINE, CA--(Marketwired - Mar 8, 2017) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce the anticipated delivery of the first of our pre-designed greenhouses with full tracking and reporting protocols to be delivered this week for our California and Nevada operations.
"Having control over our own supply chain will greatly increase our efficiencies, including the time and cost required to have processed product readily available for development into all our formulations. We will soon launch our observational studies for specific cannabinoid combinations targeting critical ailments. We will be growing a variety of cannabinoid combinations for our formulations and testing. Each formulation is designed to target a specific critical ailment; to work using a particular delivery mode; and to have the potency to drive maximum positive results in patient usage," stated CMO Dr. Allen Herman.
CBIS, Inc. has received several hundred emails inquiring about the timing of clinical research and the availability of treatment options. These inquiries cover the management of pain, peripheral neuropathies, cancer, and COPD. All inquiries are entered into our in-house database and we will be responding to each person as each targeted observational study officially commences. The studies will include some of the over 500 cannabinoids that have been isolated and identified from Cannabis sativa. The cannabinoids belong to the chemical class of terpenophenolics, of which 85 have been uniquely identified in cannabis. Common plant cannabinoids (phytocannabinoids) include: tetrahydrocannabinol (THC), cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), and cannabinol (CBN). The pharmacology of THC has been widely studied, and it is regarded as the main psychoactive constituent of cannabis. Our in-house database will form the basis of patient-centered outcomes research (PCOR) for a variety of critical conditions.
CBIS will then develop protocols for our international consortium of US, South African, and European universities and research institutions. This consortium will develop research protocols for animal studies and clinical trials for several critical clinical ailments concurrently. The Cannabis Science Research Laboratory will have principal investigators at each partner institution and will work closely with CBIS leadership. Our initial animal studies will focus on cancers, and our clinical trials will concentrate on Cancers, PTSD, pain management, HIV/AIDS, and neurological conditions including sleep disorders. CBIS will then add other targeted ailments for clinical trials as the demand and need is identified in each jurisdiction. Each country that we collaborate in will ensure that the research is done within the approval guidelines for that country and follows the approval guidelines for the US Food and Drug Administration providing nationwide federal government approvals.
IRVINE, CA--(Marketwired - Mar 8, 2017) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce the anticipated delivery of the first of our pre-designed greenhouses with full tracking and reporting protocols to be delivered this week for our California and Nevada operations.
"Having control over our own supply chain will greatly increase our efficiencies, including the time and cost required to have processed product readily available for development into all our formulations. We will soon launch our observational studies for specific cannabinoid combinations targeting critical ailments. We will be growing a variety of cannabinoid combinations for our formulations and testing. Each formulation is designed to target a specific critical ailment; to work using a particular delivery mode; and to have the potency to drive maximum positive results in patient usage," stated CMO Dr. Allen Herman.
CBIS, Inc. has received several hundred emails inquiring about the timing of clinical research and the availability of treatment options. These inquiries cover the management of pain, peripheral neuropathies, cancer, and COPD. All inquiries are entered into our in-house database and we will be responding to each person as each targeted observational study officially commences. The studies will include some of the over 500 cannabinoids that have been isolated and identified from Cannabis sativa. The cannabinoids belong to the chemical class of terpenophenolics, of which 85 have been uniquely identified in cannabis. Common plant cannabinoids (phytocannabinoids) include: tetrahydrocannabinol (THC), cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), and cannabinol (CBN). The pharmacology of THC has been widely studied, and it is regarded as the main psychoactive constituent of cannabis. Our in-house database will form the basis of patient-centered outcomes research (PCOR) for a variety of critical conditions.
CBIS will then develop protocols for our international consortium of US, South African, and European universities and research institutions. This consortium will develop research protocols for animal studies and clinical trials for several critical clinical ailments concurrently. The Cannabis Science Research Laboratory will have principal investigators at each partner institution and will work closely with CBIS leadership. Our initial animal studies will focus on cancers, and our clinical trials will concentrate on Cancers, PTSD, pain management, HIV/AIDS, and neurological conditions including sleep disorders. CBIS will then add other targeted ailments for clinical trials as the demand and need is identified in each jurisdiction. Each country that we collaborate in will ensure that the research is done within the approval guidelines for that country and follows the approval guidelines for the US Food and Drug Administration providing nationwide federal government approvals.
(0)
(0)